REGULATED PRESS RELEASE published on 02/25/2026 at 18:31, 6 months 13 days ago Saint-Gobain continues its development in construction chemicals by entering the Dominican Republic and strengthening its position in Benelux Saint-Gobain strengthens its construction chemicals division by acquiring Morteros de Europa in the Dominican Republic and Grouttech in Benelux, in line with its strategic plan Acquisition Saint-Gobain Construction Chemicals Strategic Plan Dominican Republic
REGULATED PRESS RELEASE published on 02/25/2026 at 18:31, 6 months 13 days ago Saint-Gobain continue son développement dans la chimie de la construction en entrant en République dominicaine et en renforçant sa présence au Benelux Saint-Gobain renforce sa présence en chimie de construction en République dominicaine et au Benelux avec acquisitions stratégiques Saint-Gobain Acquisitions Benelux République Dominicaine Chimie De Construction
PRESS RELEASE published on 02/25/2026 at 18:25, 6 months 13 days ago EQS-Adhoc: Einhell Germany AG: Preliminary business figures for 2025 Einhell Germany AG announces record sales and earnings for 2025, with a pre-tax return of 9.3%. Solid balance sheet with sales forecasted at EUR 1,200 million for 2026 Record Sales Earnings Einhell Germany AG Pre-tax Return 2026 Forecast
PRESS RELEASE published on 02/25/2026 at 18:00, 6 months 13 days ago Diginex Limited signs Abu Dhabi Sustainable Finance Declaration and deepens engagement with ADGM’s Sustainable Finance Community as UAE Climate Law reshapes disclosure expectations for the region Diginex Limited signs Abu Dhabi Sustainable Finance Declaration and deepens engagement with ADGM’s Sustainable Finance Community as UAE Climate Law reshapes disclosure expectations for the region ESG Sustainable Finance Abu Dhabi Diginex Limited UAE Climate Law
PRESS RELEASE published on 02/25/2026 at 18:00, 6 months 13 days ago NR21: Communiqué sur les résultats annuels 2025 Communiqué sur les résultats annuels 2025 de NR21, une société en commandite par actions sans activité en 2025, contrôlée par Altarea. Détails financiers et perspectives d'investissement Résultats Annuels Investissements Bilan NR21 Bénéfice
PRESS RELEASE published on 02/25/2026 at 18:00, 6 months 13 days ago freenet increases dividend to EUR 2.07 and achieves record growth in postpaid customers and IPTV EBITDA freenet AG increases dividend to EUR 2.07, achieves record postpaid customer growth & IPTV EBITDA. New CEO focuses on 'AI-first' strategy. Stable financial figures for 2025 Financial Results Dividend Increase Freenet AG Postpaid Customers IPTV EBITDA
REGULATED PRESS RELEASE published on 02/25/2026 at 18:00, 6 months 13 days ago Augmentation de capital réservée aux salariés du groupe Eiffage Eiffage annonce une augmentation de capital réservée aux salariés dans 9 pays, avec décote de 20%, émission d'actions à 106,55€, souscription via FCPE, période du 23/03 au 13/04/2026 Eiffage Actions Augmentation De Capital Salariés FCPE
PRESS RELEASE published on 02/25/2026 at 18:00, 6 months 13 days ago Alan Allman Associates enregistre un chiffre d'affaires de 81,3 M EUR au quatrième trimestre 2025 et de 330,4 M EUR en 2025 Alan Allman Associates annonce un chiffre d'affaires de 81,3 M€ au T4 2025, en baisse de 10,4% par rapport à 2024, et de 330,4 M€ en 2025. L'Ecosystème se recentre sur ses expertises clés et vise une amélioration de sa performance en 2026 Chiffre D'affaires Stratégie Transformation Digitale Alan Allman Associates T4 2025
PRESS RELEASE published on 02/25/2026 at 18:00, 6 months 13 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV in Leuven received a transparency notification from Atlas Special Opportunities II, LLC indicating a change in shareholding. The company specializes in acquiring stakes in European pharmaceutical subcontractors Transparency Notification Shareholding Change Oxurion NV Belgian Transparency Legislation Pharmaceutical Subcontractors
PRESS RELEASE published on 02/25/2026 at 18:00, 6 months 13 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV (Euronext Brussel: OXUR) ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC over verkoop van aandelen en specialiseert in Europese farmaceutische onderaannemers. Toekomstgerichte verklaringen bevatten risico's en onzekerheden Transparantiekennisgeving Euronext Brussel Oxurion NV Farmaceutische Onderaannemers Toekomstgerichte Verklaringen
Published on 09/11/2026 at 17:00, 45 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 45 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 2 hours 20 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 2 hours 45 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 3 hours 15 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 17:30, 14 minutes ago NAGRAVISION and Plume Strengthen Connected Home Security for 30 Million Subscribers Worldwide
Published on 09/11/2026 at 16:30, 1 hour 15 minutes ago Belt and Road Summit in Hong Kong welcomes over 6,200 global leaders to explore new business opportunities
Published on 09/11/2026 at 16:00, 1 hour 45 minutes ago Deutsche Postbank Funding Trust III published semi-annual report
Published on 09/11/2026 at 16:00, 1 hour 45 minutes ago Form 8.3 - IPConcept (Luxemburg) S.A.: SONNTAG Premium
Published on 09/11/2026 at 07:00, 10 hours 45 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 10 hours 45 minutes ago Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 10 hours 45 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 10 hours 45 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 22 hours 15 minutes ago Availability of the 2026 Interim Financial Report